Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway

Frontiers Editorial Office,

doi:10.3389/fphys.2022.1020568

RETRACTION article

Front. Physiol. , 24 August 2022

Sec. Mitochondrial Research

Volume 13 - 2022 | https://doi.org/10.3389/fphys.2022.1020568

This article is part of the Research Topic Role of Mitochondrial Quality Control in Myocardial and Microvascular Physiology and Pathophysiology View all 43 articles

Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway

This article is a retraction of:

RETRACTED: MiR-22 Inhibition Alleviates Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy by Targeting the sirt1/PGC-1α Pathway
1. Read original article

Frontiers Editorial Office*

A retraction of the Original Research article
MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway

by Wang R, Xu Y, Niu X, Fang Y, Guo D, Chen J, Zhu H, Dong J, Zhao R, Wang Y, Qi B, Ren G, Li X, Liu L and Zhang M (2021) Front. Physiol. 12:646903. doi: 10.3389/fphys.2021.646903

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.

Given the concerns, the editors no longer have confidence in the findings presented in the article.

During correspondence, the authors did not respond to the question of whether they agree or disagree to the retraction.

This retraction was approved by the Chief Editors of Frontiers in Physiology and the Chief Executive Editor of Frontiers.

Citation: Frontiers Editorial Office (2022) Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway. Front. Physiol. 13:1020568. doi: 10.3389/fphys.2022.1020568

Received: 16 August 2022; Accepted: 16 August 2022;
Published: 24 August 2022.

Approved by:

Amadou K. S. Camara, Medical College of Wisconsin, United States

Copyright © 2022 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, ZWRpdG9yaWFsLm9mZmljZUBmcm9udGllcnNpbi5vcmc=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Retraction: MiR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1α pathway

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good